bluuebunny/crossref_metadata_2025 huggingface dataset:
Tests of human auditory temporal resolution: Simulations of Bayesian threshold estimation for auditory gap detection
Authors: Mori Shuji , Murata Yuto , Morimoto Takashi , Okamoto Yasuhide , Kanzaki Sho
Published: September 2024

In an attempt to develop tests of auditory temporal resolution using gap detection, we conducted computer simulations of Zippy Estimation by Sequential Testing (ZEST), an adaptive Bayesian threshold estimation procedure, for measuring gap detection thresholds. The results showed that the measures of efficiency and precision of ZEST changed with the mean and standard deviation (SD) of the initial probability density function implemented in ZEST. Appropriate combinations of mean and SD values led to efficient ZEST performance; i.e., the threshold estimates converged to their true values after 10 to 15 trials.
Structural and functional effects of phosphopriming and scaffolding in the kinase GSK-3β
Authors: Enos Michael D. , Gavagan Maire , Jameson Noel , Zalatan Jesse G. , Weis William I.
Published: September 2024

Glycogen synthase kinase 3β (GSK-3β) targets specific signaling pathways in response to distinct upstream signals. We used structural and functional studies to dissect how an upstream phosphorylation step primes the Wnt signaling component β-catenin for phosphorylation by GSK-3β and how scaffolding interactions contribute to this reaction. Our crystal structure of GSK-3β bound to a phosphoprimed β-catenin peptide confirmed the expected binding mode of the phosphoprimed residue adjacent to the catalytic site. An aspartate phosphomimic in the priming site of β-catenin adopted an indistinguishable structure but reacted approximately 1000-fold slower than the native phosphoprimed substrate. This result suggests that substrate positioning alone is not sufficient for catalysis and that native phosphopriming interactions are necessary. We also obtained a structure of GSK-3β with an extended peptide from the scaffold protein Axin that bound with greater affinity than that of previously crystallized Axin fragments. This structure neither revealed additional contacts that produce the higher affinity nor explained how substrate interactions in the GSK-3β active site are modulated by remote Axin binding. Together, our findings suggest that phosphopriming and scaffolding produce small conformational changes or allosteric effects, not captured in the crystal structures, that activate GSK-3β and facilitate β-catenin phosphorylation. These results highlight limitations in our ability to predict catalytic activity from structure and have potential implications for the role of natural phosphomimic mutations in kinase regulation and phosphosite evolution.
Probe Absorption Spectroscopy As a Tool to Study the Excited States in a Cooperative System of Two Organic Molecules
Authors: Tarasevich E. A. , Gladush M. G.
Published: September 2024

The applicability of the method for measuring the probe absorption and gain spectra in a system of quantum emitters excited by a resonant driving field for studying cooperative photoluminescence is considered. The gain and attenuation of a probe signal in the system of two quantum emitters with the dipole–dipole interaction have been calculated for the conditions of observing the cooperative photoluminescence of a pair of impurity molecules described in the literature and close to them. The resulting dependences demonstrate the structure of excited collective molecular states, which can be used to reconstruct the positions of molecules in a matrix and to determine the difference in their photophysical properties. Thus, the probe absorption and gain spectra can be used to analyze the photoluminescence of quantum-entangled particles and to transform light signals.
Aeromagnetic gradiometry with UAV, a case study on small iron ore deposit
Authors: Shahsavani Hashem , Smith Richard S.
Published: September 2024

Unmanned aerial vehicles (UAVs), commonly known as drones, offer several advantages over traditional piloted aircraft. They are characterized by enhanced safety, cost-effectiveness, and the ability to operate in closer proximity to targeted sources. Consequently, magnetic sensors have been adapted or specifically designed for integration onto UAV platforms. However, existing sensors are burdened by issues such as weight, cost, and high power consumption. These challenges are particularly pronounced when employing aeromagnetic gradiometry, which necessitates simultaneous measurements from at least two sensors. In response to these limitations, we propose the implementation of a cost-effective, lightweight, and low-power magneto-inductive sensor with satisfactory resolution aboard a UAV. To evaluate its efficacy, a survey was conducted over a small iron ore deposit in Western Iran. To validate our approach, we compare the results with those obtained using only one sensor on the drone. This comparative analysis reveals that employing a gradiometry array leads to a pronounced steepening of magnetic anomaly margins. Specifically, the gradient of magnetic measurements on four selected profiles increases to 3.8, 4.6, 9.3, and 10 nT/m when utilizing the proposed magneto-inductive sensor, in contrast to the conventional method of gradient determination through mathematical derivatives in the z-direction. This research contributes to the advancement of efficient and economical methods for mineral exploration using UAV-based magnetic surveying techniques.
The nonlinear stability of (n + 1)-dimensional FLRW spacetimes
Authors: Mondal Puskar
Published: September 2024

We prove nonlinear Lyapunov stability of a family of “([Formula: see text])”-dimensional cosmological models of general relativity locally isometric to the Friedman–Lemaître–Robertson–Walker (FLRW) spacetimes including a positive cosmological constant. In particular, we show that the perturbed solutions to the Einstein–Euler field equations around a class of spatially compact FLRW metrics (for which the spatial slices are compact negative Einstein spaces in general and hyperbolic for the physically relevant [Formula: see text] case) arising from regular Cauchy data remain uniformly bounded and decay to a family of metrics with constant negative spatial scalar curvature. To accomplish this result, we employ an energy method for the coupled Einstein–Euler field equations in constant mean extrinsic curvature spatial harmonic (CMCSH) gauge. In order to handle Euler’s equations, we construct energy from a current that is similar to the one derived by Christodoulou [The Formation of Shocks in 3-dimensional Fluids, EMS Monographs in Mathematics, Vol. 2 (European Mathematical Society, 2007)] (and which coincides with Christodoulou’s current on the Minkowski space) and show that this energy controls the desired norm of the fluid degrees of freedom. The use of a fluid energy current together with the CMCSH gauge condition casts the Einstein–Euler field equations into a coupled elliptic–hyperbolic system. Utilizing the estimates derived from the elliptic equations, we first show that the gravity-fluid energy functional remains uniformly bounded in the expanding direction. Using this uniform boundedness property, we later obtain sharp decay estimates if a positive cosmological constant [Formula: see text] is included, which confirms that the accelerated expansion of the physical universe that is induced by the positive cosmological constant is sufficient to control the nonlinearities in the case of small data. A few physical consequences of this stability result are discussed.
Association between Subclinical Hypothyroidism and Glycemic Control in Older Adults in a Medical Center in Peru
Authors: Quintanilla Karen , Joo Karla M. , La Torre Hellen L. , Neyra-Rivera Carlos D. , Gutierrez Ericson L. , Parodi José F. , Runzer-Colmenares Fernando M.
Published: September 2024

Objective. To determine whether there is an association between subclinical hypothyroidism and glycemic control in older adults who received care at the “Centro Médico Naval” from 2010 to 2015. Methods. This retrospective analytical study analyzed a secondary database of the care of elderly in the study hospital. The sample was comprised of 1,385 older adults. To detect an association between variables, the Poisson regression with robust variance was used at a significance level of 95%. The analyses were carried out with the STATA 16 program. Results. Of the elderly 45.6% were between 71 and 80 years old; 58.4% were women and 43.8% had a normal body mass index. There was evidence of inadequate glycemic control in 8.1% and subclinical hypothyroidism in 15.2% of the elderly patients. Subclinical hypothyroidism was more frequent in the inadequate glycemic control vs. adequate glycemic control populations (41.1% vs. 13.0%). In the multivariance analysis, subclinical hypothyroidism (aPR = 2.22 95% CI [1.47–3.36]) was independent factor associated with inadequate glycemic control (p < 0.001). Conclusions. A significant association was detected between subclinical hypothyroidism and inadequate glycemic control in older adults who presented at the “Centro Médico Naval” from 2010 to 2015.
Complications and Influential Perioperative Factors Associated with SpaceOAR Hydrogel Placement
Authors: Wang Kerith R. , Simhal Rishabh K. , Clark Cassra B. , Mann Mark J. , Mark James R. , Lallas Costas D. , Den Robert , Trabulsi Edouard J.
Published: September 2024

Objective. To examine one academic institution’s experiences with SpaceOAR placement, its associated complications, and periprocedural characteristics that affect outcomes for the purpose of quality improvement. Materials and Methods. We conducted a retrospective review of 233 patients who received SpaceOAR from four surgeons and one radiation oncologist between 2018 and 2021. Variables such as demographics, oncologic parameters, radiation plan, and radiographic assessment of hydrogel placement were recorded. The Charlson Comorbidity Index (CCI) was used to assess comorbidity risk. Mann–Whitney and Fisher’s exact tests were performed to compare patients with and without complications. Results. Of the 233 patients who received SpaceOAR, 24 (10.3%) experienced toxicity. All complications were Clavien I or II, such as pelvic pain postplacement, pelvic fullness, bleeding, and lower urinary tract symptoms. 16 patients (6.9%) had some portion of the hydrogel injected into the rectal wall, but it was never clinically significant. The average CCI was 3.2 ± 0.95 for patients who experienced complications; the average CCI was 3.6 ± 1.6 (p = 0.48) in the group without complications. Of the physicians with higher procedure volumes, Physician #1 had the highest rate of patient‐reported complications at 11 out of 68 (16.2%) and Physician #2 had the lowest rate of complications at 4 out of 96 placements (4.2%). Multivariate analysis found that patients who had received hormone therapy previously had less odds of reporting complications after SpaceOAR placement. Conclusions. The listed attending on the procedure had a significant correlation to complications with SpaceOAR placement on univariate analysis, and hormone therapy had some benefits to the tolerance for the procedure on multivariate analysis. Overall, the hydrogel placement was well tolerated with low incidence of mild and transient procedure‐related toxicity.
Sensitive Properties of Power Spectral Density Transmissibility (PSDT) to Moving Vehicles and Structural States in Bridge Health Monitoring
Authors: Qin Li-Feng , Ren Wei-Xin , Yan Wang-Ji
Published: September 2024

Bridge health monitoring confronts a critical challenge in extracting meaningful features that are sensitive to structural damage while remaining nonsensitive to operational environments and loads. Most of structural response features such as power spectral density (PSD) in the long‐term monitored bridge are influenced by operational vehicle loads. The power spectral density transmissibility (PSDT), defined as the power spectral density ratio of two measured output responses at two different structural locations with the same reference output response, converges independently at the system poles of the applied excitations and transferring outputs. Capitalizing on such a unique property of PSDT around the system poles, the PSDT‐based spectral moment is proposed in the paper to establish a robust structural feature in bridge health monitoring taking into account the time‐varying characteristics under operational vehicle loads. Numerical simulations and comparisons with PSD‐based spectral moment analysis reveal that the PSDT‐based spectral moment exhibits an enhanced robustness to traffic flow excitations and heightened sensitivity to changes in structural parameters. Further laboratory experimental results on the beam under moving vehicle confirm that the PSDT‐based spectral moment is less affected by moving vehicle loads, but it demonstrates higher sensitivity to structural parameter changes. Given its robust properties of low sensitivity to operational vehicle loads and sensitivity to changes in structural parameters, the proposed PSDT‐based spectral moment emerges as an ideal structural feature suitable for the effective applications in the long‐term bridge health monitoring, such as structural damage identification, model updating, condition assessment, and safety warning.
The Effect of 8‐Week Protein Supplementation with a Simple Exercise Program on Body Composition, Muscle Strength, and Amino Acid OMICS among Healthy Sedentary Indians: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Authors: Sambashivaiah Sucharita , Marathe Madhavi , Bhadra Rohini , Bhattacharya Shinjini , Selvam Sumithra
Published: September 2024

Dietary protein plays a crucial role in the modulation of several physiological processes to sustain health and well‐being. There is robust evidence of enhanced muscle protein synthesis, improved physical fitness, body composition, and performance contributed by protein supplementation combined with exercise among trained individuals or athletes. Evidence of the efficacy of such intervention on healthy adults having a sedentary lifestyle is limited. The objective of this study was to evaluate the impact of 12 g of additional protein in the form of a protein supplement compared to a placebo combined with a simple exercise program on plasma amino acid level, body composition, and muscle strength among healthy Indian adults having a relatively sedentary lifestyle. This double‐blinded, randomized controlled trial was conducted on sedentary healthy adults 20–45 years of age, with a body mass index (BMI) between 18.5 and 27.9 kg/m2. Eighty‐two participants were randomized into either the protein (intervention) or placebo (control) group. The exercise regime was the same for both groups. Out of 82 randomized participants, 58 completed the intervention. Blood tests were conducted for the amino acid OMICS measurement followed by dual‐energy X‐ray absorptiometry (DXA) for body composition and isokinetic dynamometry for muscle strength. A significant improvement was observed in the lean mass (kg) and appendicular muscle mass (AMM) adjusted for weight in the intervention group compared to the control group (p < 0.05). The muscle strength and contractile quality were comparable in the 2 groups. Plasma BCAA showed a significant negative association with body fat % (r = −0.43, p < 0.05 for the intervention group and r = −0.33, p = 0.07 for the control group) and a positive association with lean body mass % (r = 0.56, p < 0.01 in the intervention group vs r = 0.29, p = 0.10 in the control group) in the intervention group compared to control. In conclusion, this study highlighted the value of incorporating a lifestyle intervention including protein supplementation with simple exercises to optimize body composition in sedentary healthy individuals. This trial is registered with CTRI/2018/12/016777.
“I Think I Could Have Used It Better”: Experiences of Youth with High HbA1c Commencing Advanced Hybrid Closed‐Loop Therapy in a Clinical Trial Setting—A Qualitative Research
Authors: Roberts Alison , Dart Julie , Lloyd Selena , Bebbington Keely , Fairchild Janice M. , Ambler Geoffrey R. , Cameron Fergus J. , Davis Elizabeth A. , Jones Timothy W. , Abraham Mary B.
Published: September 2024

Background. Advanced hybrid closed‐loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes‐related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting. Methods. This was a singlecenter substudy of a multicenter 6‐month randomized clinical trial. Youth between 12 and 25 years of age on insulin pump therapy with HbA1c > 8.5% (> 69 mmol/mol) who commenced AHCL therapy with Medtronic MiniMed™ system were invited to participate in a semistructured interview after 6 months of AHCL. Open‐ended questions were used to explore the participants’ lived experience of AHCL in improving their glucose levels and its impact on diabetes management and well‐being. The interviews were audiorecorded, transcribed, and analyzed using thematic analysis. Results. Ten youth with T1D with a mean (SD) age of 17.4 (2.9) years, diabetes duration 10.7 (4.8) years, HbA1c 10.2 (0.8)%, or 87 (9.5) mmol/mol at enrollment participated in the interview. Three main themes were identified: (1) improved glycemia despite not using closed loop to its full potential; (2) persistent diabetes burden; and (3) a need for increased psychosocial and clinical support. Although improved glycemia was noted with AHCL therapy, participants reported ongoing motivation issues and used the system suboptimally. They continued to experience distress with overall diabetes management and acknowledged the need for ongoing support from family and health professionals. Conclusion. All participants reported overall satisfaction with improved glucose levels, however, the persistent diabetes burden impacted their ability to use AHCL optimally. The need for ongoing monitoring with support and interventions to enhance psychological care remains vital for youth with suboptimal diabetes management.
Supplementary Table S8 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Table S8. CVD-related Standardized Mortality Ratios in older patient with different types of hematological malignancies based on years after diagnosis.
Supplementary Table S2 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Table S2. The subclassifications and ICD-10 codes used for defining cardiovascular disease.
Supplementary Figure S10 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Figure S10. The cumulative mortality among older patients with hematological malignancies based on different types of hematological malignancy (age at diagnosis: 65-74). For each panel, we show the cumulative mortality curve for older patients among all 7 types of hematological malignancies: acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Abbreviations: CVD, Cardiovascular Disease
Supplementary Table S1 from Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study
Authors: Friedman Danielle N. , Chou Joanne F. , Clark Jeanne M. , Moskowitz Chaya S. , Ford Jennifer S. , Armstrong Gregory T. , Mubdi Nidha Z. , McDonald Aaron , Nathan Paul C. , Sklar Charles A. , Ramanathan Lakshmi V. , Robison Leslie L. , Oeffinger Kevin C. , Tonorezos Emily S.
Published: September 2024

Supplementary Table S1. Baseline characteristics of participants compared to non-participants.
Supplementary Table S5 from Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Authors: Trendowski Matthew R. , Watza Donovan , Lusk Christine M. , Lonardo Fulvio , Ratliff Valerie , Wenzlaff Angela S. , Mamdani Hirva , Neslund-Dudas Christine , Boerner Julie L. , Schwartz Ann G. , Gibson Heather M.
Published: September 2024

Genes Differentially Expressed by PD-L1 Expression or TLS Status and Differentially Expressed by Race.
Supplementary Table S4 from Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Authors: Trendowski Matthew R. , Watza Donovan , Lusk Christine M. , Lonardo Fulvio , Ratliff Valerie , Wenzlaff Angela S. , Mamdani Hirva , Neslund-Dudas Christine , Boerner Julie L. , Schwartz Ann G. , Gibson Heather M.
Published: September 2024

Logistic Regression Results of PD-L1 Expression and Immune Gene Expression (ppooled < 0.05).
Supplementary Table S2 from Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Authors: Trendowski Matthew R. , Watza Donovan , Lusk Christine M. , Lonardo Fulvio , Ratliff Valerie , Wenzlaff Angela S. , Mamdani Hirva , Neslund-Dudas Christine , Boerner Julie L. , Schwartz Ann G. , Gibson Heather M.
Published: September 2024

Overall Survival by PD-L1 and TLS Status.
Supplementary Table S1 from Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Authors: Trendowski Matthew R. , Watza Donovan , Lusk Christine M. , Lonardo Fulvio , Ratliff Valerie , Wenzlaff Angela S. , Mamdani Hirva , Neslund-Dudas Christine , Boerner Julie L. , Schwartz Ann G. , Gibson Heather M.
Published: September 2024

Clinical and Demographic Characteristics by PD-L1 and TLS Status.
Supplementary Table 3 from Risk and Prognosis of Cancer in Patients with Obstructive Uropathy Compared with the General Danish Population
Authors: Nørgaard Mette , Körmendiné Farkas Dóra , Gotschalck Madeleine A. , Sørensen Henrik Toft
Published: September 2024

Adjusted mortality rate ratios (MRR) for cancer patients with obstructive uropathy (OU) compared with cancer patients without OU according to cancer type and time between OU and cancer diagnosis
Supplementary Figure 1 from Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants
Authors: Cramer Daniel W. , Vitonis Allison F. , Fichorova Raina N. , Yamamoto Hidemi S. , Mudugno Francesmary , Finn Olivera J.
Published: September 2024

Supplementary Figure 1. Distributions of CA15.3 antigens and antibodies.
Supplementary Table 2 from Risk and Prognosis of Cancer in Patients with Obstructive Uropathy Compared with the General Danish Population
Authors: Nørgaard Mette , Körmendiné Farkas Dóra , Gotschalck Madeleine A. , Sørensen Henrik Toft
Published: September 2024

1-year and 5-year overall mortality and adjusted MRR for patients diagnosed with cancer by time after a diagnosis of OU (within 1 year and more than 1 year after OU) and 69,785 cancer patients without OU
Data from Risk and Prognosis of Cancer in Patients with Obstructive Uropathy Compared with the General Danish Population
Authors: Nørgaard Mette , Körmendiné Farkas Dóra , Gotschalck Madeleine A. , Sørensen Henrik Toft
Published: September 2024

AbstractBackground:
To examine whether obstructive uropathy is associated with increased risk of cancer and whether mortality differs between patients with cancer with and without obstructive uropathy.
Methods:
In a nationwide population-based Danish cohort study including 37,275 adult patients with a first-time hospital-related diagnosis of obstructive uropathy in 1996 to 2022, we assessed cumulative cancer incidence (risk) and standardized incidence ratios (SIR). Furthermore, we compared the mortality of 7,485 patients diagnosed with cancer after obstructive uropathy diagnosis with that of 69,785 patients with cancer without obstructive uropathy matched by age, sex, cancer site, stage, and calendar year of cancer diagnosis.
Results:
The 3-month risk of cancer after an obstructive uropathy diagnosis was 9.6%. The 3-month SIR was 34.2 [95% confidence interval (CI), 33.1–35.4] while the 1 to <5 year SIR was 1.2 (95% CI, 1.1–1.3). The 3-month SIRs were 82.7 (95% CI, 79.3–86.2) for urological cancer, 88.8 (95% CI, 79.8–98.5) for gynecological cancer, and 13.9 (95% CI, 12.0–15.9) for colorectal cancer. After 1 year of follow-up, the excess number of urological cancers decreased to 0.1 per 100 person-years, whereas we observed no excess risk of gynecological and colorectal cancers. The 5-year all-cause mortality following cancer was 64.1% (95% CI, 62.9–65.2) in patients with an obstructive uropathy diagnosis before cancer diagnosis and 53.2% (95% CI, 52.9–53.6) in those without.
Conclusions:
A first-time diagnosis of obstructive uropathy can be a clinical marker of underlying undiagnosed cancer and elevated mortality in relation to any cancer diagnosed after obstructive uropathy.
Impact:
These findings can inform the follow-up recommendations for obstructive uropathy.
Supplementary Table S3 from Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning
Authors: Reinecke David , Ruess Daniel , Meissner Anna-Katharina , Fürtjes Gina , von Spreckelsen Niklas , Ion-Margineanu Adrian , Khalid Florian , Blau Tobias , Stehle Thomas , Al-Shugri Abdulkader , Büttner Reinhard , Goldbrunner Roland , Ruge Maximilian I. , Neuschmelting Volker
Published: September 2024

Supplementary Table S3. The second model was tested on small biopsy tissue samples to classify each acquired entity into subclasses, e.g., pilocytic astrocytoma, diffuse low-grade glioma, high-grade glioma, lymphoma, metastases, and gliosis. The corresponding class predictions are compared to the final neuropathological diagnosis.
Supplementary Table S2 from Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning
Authors: Reinecke David , Ruess Daniel , Meissner Anna-Katharina , Fürtjes Gina , von Spreckelsen Niklas , Ion-Margineanu Adrian , Khalid Florian , Blau Tobias , Stehle Thomas , Al-Shugri Abdulkader , Büttner Reinhard , Goldbrunner Roland , Ruge Maximilian I. , Neuschmelting Volker
Published: September 2024

Supplementary Table S2. The first model illustrates each collected entity with corresponding class predictions (CP). It classifies small biopsy tissue samples as tumorous or non-tumorous tissue; accuracy depends on the final diagnosis (FD).
Supplementary Figure S2 from Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning
Authors: Reinecke David , Ruess Daniel , Meissner Anna-Katharina , Fürtjes Gina , von Spreckelsen Niklas , Ion-Margineanu Adrian , Khalid Florian , Blau Tobias , Stehle Thomas , Al-Shugri Abdulkader , Büttner Reinhard , Goldbrunner Roland , Ruge Maximilian I. , Neuschmelting Volker
Published: September 2024

Supplementary Figure S2. Illustration of two SRH images with different signal-to-noise ratios due to ambient temperature and autofocus variability.
Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Authors: Lentz Robert W. , Friedrich Tyler J. , Blatchford Patrick J. , Jordan Kimberly R. , Pitts Todd M. , Robinson Hannah R. , Davis S. Lindsey , Kim Sunnie S. , Leal Alexis D. , Lee Mathew R. , Waring Meredith R.N. , Martin Anne C. , Dominguez Adrian T.A. , Bagby Stacey M. , Hartman Sarah J. , Eckhardt S. Gail , Messersmith Wells A. , Lieu Christopher H.
Published: September 2024

Supplementary Figure S5. Overall survival in patients with or without baseline liver metastases.
Supplementary Figure S4 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Authors: Lentz Robert W. , Friedrich Tyler J. , Blatchford Patrick J. , Jordan Kimberly R. , Pitts Todd M. , Robinson Hannah R. , Davis S. Lindsey , Kim Sunnie S. , Leal Alexis D. , Lee Mathew R. , Waring Meredith R.N. , Martin Anne C. , Dominguez Adrian T.A. , Bagby Stacey M. , Hartman Sarah J. , Eckhardt S. Gail , Messersmith Wells A. , Lieu Christopher H.
Published: September 2024

Supplementary Figure S4. Progression-free survival in patients with or without baseline liver metastases.
Supplementary Figure S2 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Authors: Lentz Robert W. , Friedrich Tyler J. , Blatchford Patrick J. , Jordan Kimberly R. , Pitts Todd M. , Robinson Hannah R. , Davis S. Lindsey , Kim Sunnie S. , Leal Alexis D. , Lee Mathew R. , Waring Meredith R.N. , Martin Anne C. , Dominguez Adrian T.A. , Bagby Stacey M. , Hartman Sarah J. , Eckhardt S. Gail , Messersmith Wells A. , Lieu Christopher H.
Published: September 2024

Supplementary Figure S2. Progression-free survival in the randomized cohorts.
Supplementary Figure S1 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Authors: Lentz Robert W. , Friedrich Tyler J. , Blatchford Patrick J. , Jordan Kimberly R. , Pitts Todd M. , Robinson Hannah R. , Davis S. Lindsey , Kim Sunnie S. , Leal Alexis D. , Lee Mathew R. , Waring Meredith R.N. , Martin Anne C. , Dominguez Adrian T.A. , Bagby Stacey M. , Hartman Sarah J. , Eckhardt S. Gail , Messersmith Wells A. , Lieu Christopher H.
Published: September 2024

Supplementary Figure S1. CEA kinetics in patients with stable disease at first response assessment.
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Authors: Lee Horace H.Y. , Chow Kin Long , Wong Ho Shing , Chong Tsz Yan , Wong Alice S.T. , Cheng Grace H.W. , Ko Jasmine M.K. , Siu Hoi Cheong , Yeung Maximus C.F. , Huen Michael S.Y. , Tse Ka Yu , Bray Mark R. , Mak Tak Wah , Leung Suet Yi , Ip Philip P.C.
Published: September 2024

Supplementary Table S1. Clinicopathologic features of 25 uterine leiomyosarcoma.
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Authors: Lee Horace H.Y. , Chow Kin Long , Wong Ho Shing , Chong Tsz Yan , Wong Alice S.T. , Cheng Grace H.W. , Ko Jasmine M.K. , Siu Hoi Cheong , Yeung Maximus C.F. , Huen Michael S.Y. , Tse Ka Yu , Bray Mark R. , Mak Tak Wah , Leung Suet Yi , Ip Philip P.C.
Published: September 2024

Supplementary Figure S6. Genomic alterations involving key genes responsible for DNA repair in uterine leiomyosarcoma.
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Authors: Lee Horace H.Y. , Chow Kin Long , Wong Ho Shing , Chong Tsz Yan , Wong Alice S.T. , Cheng Grace H.W. , Ko Jasmine M.K. , Siu Hoi Cheong , Yeung Maximus C.F. , Huen Michael S.Y. , Tse Ka Yu , Bray Mark R. , Mak Tak Wah , Leung Suet Yi , Ip Philip P.C.
Published: September 2024

Supplementary Data S1. Small variants, copy number alterations, structural variants, and fusion transcripts of DNA repair genes.
Table S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Table S2. Evaluated marker gene sets.
Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Figure S4. Mutational landscape stratified by cohort.
Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Figure S3. Correlation between TML and TMB.
Figure S2 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Figure S2. Best overall responses for all evaluable patients.
Supplemental Table 2 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Authors: Lenis Andrew T. , Ravichandran Vignesh , Brown Samantha , Alam Syed M. , Katims Andrew , Truong Hong , Reisz Peter A. , Vasselman Samantha , Nweji Barbara , Autio Karen A. , Morris Michael J. , Slovin Susan F. , Rathkopf Dana , Danila Daniel , Woo Sungmin , Vargas Hebert A. , Laudone Vincent P. , Ehdaie Behfar , Reuter Victor , Arcila Maria , Berger Michael F. , Viale Agnes , Scher Howard I. , Schultz Nikolaus , Gopalan Anuradha , Donoghue Mark T.A. , Ostrovnaya Irina , Stopsack Konrad H. , Solit David B. , Abida Wassim
Published: September 2024

Supplemental Table 2
Supplementary Figure S4 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: French Jena D. , Haugen Bryan R. , Worden Francis P. , Bowles Daniel W. , Gianoukakis Andrew G. , Konda Bhavana , Dadu Ramona , Sherman Eric J. , McCue Shaylene , Foster Nathan R. , Nikiforov Yuri E. , Farias Ticiana D.J. , Norman Paul J. , Wirth Lori J.
Published: September 2024

Flow cytometry gating strategy in PBMC
Supplementary Table S4 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Cell line H3K27ac SCLC Risk Scores by molecular subtype.
Supplementary Figure S2 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Epigenomic datasets generated from lung cancer PDXs.
Supplementary Figure S11 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Number of base pairs covered by differential H3K27ac, DNA methylation, and open chromatin sites enriched in LUAD or SCLC PDXs after removal of peaks also present in white blood cells.
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
Authors: Pakola Santeri A. , Peltola Katriina J. , Clubb James H.A. , Jirovec Elise , Haybout Lyna , Kudling Tatiana V. , Alanko Tuomo , Korpisaari Riitta , Juteau Susanna , Jaakkola Marjut , Sormunen Jorma , Kemppainen Jukka , Hemmes Annabrita , Pellinen Teijo , van der Heijden Mirte , Quixabeira Dafne C.A. , Kistler Claudia , Sorsa Suvi , Havunen Riikka , Santos Joao M. , Cervera-Carrascon Victor , Hemminki Akseli
Published: September 2024

A, Volume and PET signal changes in patient 20103 with metastatic anaplastic thyroid carcinoma, showing disappearance of PET signal for injected abdominal lesion, and disappearance of mesenteric and pulmonal lesions by PET and CT. B, Changes in PET signal in patient 20202 with metastatic NSCLC, showing decrease in PET signal for injected (62% SUVmax decrease) and non-injected lesion (54% SUVmax decrease). C, Visual changes in tumor in patient 20108 with adenocystic adenocarcinoma of the head and neck, showing marked necrosis of the tumor post-treatment.
Supplementary Table S8 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S8. Comparison of EBV-positive and EBV-negative cHL.
Supplementary Table S3 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S3. Cell type definitions.
Supplementary Table S12 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S12. HRS cell aggregates.
Supplementary Data 1 from Playing Russian Roulette: Parent and Adolescent Perspectives on Tumor Surveillance for Adolescents with Cancer Predisposition Syndromes
Authors: Elias Rachel , Blake Alise , Dean Lori , Flynn Jessica S. , Sachner Leila , Harrison Lynn , McGee Rose B. , Nichols Kim E. , Howard Sharp Katianne M.
Published: September 2024

Qualitative questions asked and surveillance guidelines of cancer predisposition syndromes included
Supplementary Table S1 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Table S1. Patient characteristics.
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
Supplementary Figure S9 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Figure S9. Gene expression landscape of EBV-related cHL.
Supplementary Figure S7 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Figure S7. EBV-positive MC tumors contain a T cell rich activated TME.
Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Figure 1. Consort Diagram.
Supplementary Figure S4 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Supplementary Figure S4
Supplementary Table S3 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors: Jank Paul , Karn Thomas , van Mackelenbergh Marion , Lindner Judith , Treue Denise , Huober Jens , Engels Knut , Solbach Christine , Diebold Kurt , Marmé Frederik , Müller Volkmar , Schneeweiss Andreas , Sinn Hans-Peter , Fehm Tanja , Schem Christian , Stickeler Elmar , Fasching Peter , Budczies Jan , Felder Bärbel , Nekljudova Valentina , Holtschmidt Johannes , Untch Michael , Denkert Carsten , Loibl Sibylle
Published: September 2024

pCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
Supplementary Table S1 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors: Jank Paul , Karn Thomas , van Mackelenbergh Marion , Lindner Judith , Treue Denise , Huober Jens , Engels Knut , Solbach Christine , Diebold Kurt , Marmé Frederik , Müller Volkmar , Schneeweiss Andreas , Sinn Hans-Peter , Fehm Tanja , Schem Christian , Stickeler Elmar , Fasching Peter , Budczies Jan , Felder Bärbel , Nekljudova Valentina , Holtschmidt Johannes , Untch Michael , Denkert Carsten , Loibl Sibylle
Published: September 2024

Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
Supplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.
Supplementary Figure S6 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S6. Epithelial cell type heterogeneity comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT).
Supplementary Figure S5 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Figure S5. Cellular heterogeneity comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by immunofluorescence staining.